Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells 1,510 Shares of Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Tolga Tanguler sold 1,510 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, January 12th. The stock was sold at an average price of $362.87, for a total value of $547,933.70. Following the transaction, the executive vice president directly owned 29,728 shares of the company’s stock, valued at $10,787,399.36. This trade represents a 4.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Alnylam Pharmaceuticals Price Performance

ALNY stock traded down $3.10 during trading on Wednesday, hitting $366.86. The stock had a trading volume of 1,250,033 shares, compared to its average volume of 1,593,122. The company’s 50 day moving average price is $423.39 and its two-hundred day moving average price is $421.94. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $495.55. The stock has a market cap of $48.47 billion, a price-to-earnings ratio of 1,528.58 and a beta of 0.32. The company has a debt-to-equity ratio of 4.45, a quick ratio of 2.49 and a current ratio of 2.54.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Root Financial Partners LLC bought a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at about $25,000. Salomon & Ludwin LLC bought a new stake in Alnylam Pharmaceuticals in the third quarter valued at $27,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth about $29,000. Atlantic Union Bankshares Corp acquired a new stake in Alnylam Pharmaceuticals during the 2nd quarter valued at $30,000. Finally, Ameriflex Group Inc. acquired a new position in Alnylam Pharmaceuticals in the third quarter worth $32,000. 92.97% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ALNY. Wells Fargo & Company boosted their price target on Alnylam Pharmaceuticals from $395.00 to $479.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 11th. Barclays increased their price objective on shares of Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. Truist Financial reduced their price target on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating for the company in a report on Thursday, January 8th. Piper Sandler reiterated an “overweight” rating and issued a $489.00 price objective (up from $449.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, October 31st. Finally, Raymond James Financial reiterated an “outperform” rating and set a $472.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday. Twenty-two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $490.96.

Alnylam Pharmaceuticals News Roundup

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Needham & Company reiterated a bullish outlook and forecasted strong price appreciation for ALNY, giving investors a counterpoint to bearish views and providing potential support for the stock. Needham Bullish Forecast
• Positive Sentiment: Alnylam presented at the J.P. Morgan Healthcare Conference (transcript available) — management used the forum to outline development priorities and the Alnylam 2030 growth plan, keeping the company in front of institutional investors. JPM Presentation Transcript
• Neutral Sentiment: Analysis pieces are digesting the Alnylam 2030 plan and new 2026 guidance; valuation write-ups provide scenarios but do not change fundamentals immediately. These pieces are useful for longer-term investors assessing the plan vs. current multiples. Valuation After 2030 Plan
• Neutral Sentiment: CEO interviews and conference coverage (video/interview links) elaborate on development goals and timelines; useful for due diligence but contain no immediate new financials. CEO Interview
• Neutral Sentiment: Industry roundups from JPM/BioWorld reference Alnylam within broader biopharma Q4 revenue and guidance commentary — helpful context but not company-specific catalysts. Bioworld JPM Coverage
• Neutral Sentiment: Reported short-interest data appears anomalous (shows zero shares and NaN changes), so it should not be treated as signal until corrected by exchanges. No link (data issue)
• Negative Sentiment: Insider selling: CEO Yvonne Greenstreet and multiple EVPs sold shares on Jan 12–13 (CEO sale ~9,577 shares; several EVPs sold 1,510–2,780 shares each). Collectively these disclosed sales totaled roughly $7M, which markets often view as a near-term negative signal even if sales are for personal/diversification reasons. CEO SEC Filing
• Negative Sentiment: Bank of America published a pessimistic price forecast for ALNY, which can weigh on sentiment among institutional and retail investors. BofA Pessimistic Forecast
• Negative Sentiment: News coverage highlighted a sharp intraday sell-off (article noting ~9% drop) after the company unveiled ambitious 2026 guidance and its Alnylam 2030 plan — the market appears to be re-pricing risk around execution and near-term guidance. Coverage of the Sell-off

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.